Detailed description of contraindications for decarvatinib

Deucravacitinib is a selective Tyk2 inhibitor mainly used to treat moderate to severe plaque psoriasis and other inflammatory diseases. Although the drug is clinically effective, not all patients are suitable for its use. First, it should be strictly contraindicated in patients with known hypersensitivity to decavatinib or any of its components. Such patients may experience severe allergic reactions after taking the drug, including rash, itching, difficulty breathing and even shock, and should avoid use to ensure safety.

Secondly, decavatinib is not recommended for pregnant and lactating women. Existing clinical data are not enough to clarify its safety to fetuses or infants, and animal experiments have shown that there may be risks of reproductive toxicity. Use during pregnancy may affect fetal development, and use during lactation may have adverse effects on the baby through milk. Therefore, women who are planning to become pregnant, are pregnant, or are breastfeeding should take effective contraceptive measures or delay medication, and choose alternative treatment options under the guidance of a doctor.

In addition, patients with severe hepatic impairment or active liver disease are not suitable for use of decarvatinib. Drugs are mainly metabolized by the liver. Abnormal liver function may lead to increased blood drug concentrations and increase the risk of drug toxicity, manifested by significantly elevated liver enzymes, jaundice and other systemic adverse reactions. Such patients need to carefully assess their liver function status before use, consider alternative drugs or adjust the dose if necessary, and closely monitor liver function indicators during medication.

Finally, decavatinib should be used with caution or avoided in patients with serious infections or who are immunocompromised. The drug regulates immune responses by inhibiting the Tyk2 signaling pathway and may increase the risk of infections, including bacterial, viral and fungal infections. Patients with active infection, tuberculosis, or chronic viral infection should wait until the infection is controlled before considering medication, while maintaining close follow-up and monitoring during treatment. Once fever, cough or other infection symptoms occur, you should seek medical treatment promptly and evaluate whether to suspend drug use.

Reference materials:https://www.drugs.com/